Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Bristol to invest $2 mil. in Houghten drug discovery collaboration by project end, lawsuit discloses.

  • News

Executive Summary

BRISTOL TO INVEST $2 MIL. IN HOUGHTEN DRUG DISCOVERY COLLABORATION upon completion of the project, which applies Houghten Pharmaceuticals Inc. subsidiary ChromaXome's combinatorial biology to Bristol-Myers Squibb's microbe library for screening of new drug leads, according to statements made in an Oct. 7 lawsuit. The wrongful termination of employment suit was brought by ChromaXome's founders against Houghten and filed in San Diego federal court.

Table

View full table

Tags:
Latest Headlines

EU: Good News For IVDs And For Future Transparency Of Medtech Compliance

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time

At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use

See All
UsernamePublicRestriction

Register

PS029063

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By